The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, to begin global late-stage testing.
Hengrui, Kailera say dual-acting obesity shot succeeds in China study
The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, to begin global late-stage testing.